Compare ALCO & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALCO | ACIU |
|---|---|---|
| Founded | 1960 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.3M | 247.6M |
| IPO Year | 1994 | 2015 |
| Metric | ALCO | ACIU |
|---|---|---|
| Price | $38.27 | $2.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $45.00 | $8.57 |
| AVG Volume (30 Days) | 18.5K | ★ 194.2K |
| Earning Date | 11-23-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.52% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $422.39 |
| Revenue Next Year | N/A | $377.85 |
| P/E Ratio | $28.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.32 | $2.10 |
| 52 Week High | $45.01 | $4.00 |
| Indicator | ALCO | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 40.56 | 37.63 |
| Support Level | $37.46 | $2.13 |
| Resistance Level | $42.05 | $2.41 |
| Average True Range (ATR) | 0.62 | 0.14 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 12.57 | 8.49 |
Alico Inc is a Florida-based agribusiness and land management company that mainly focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers the majority of the revenue as the firm's primary operating business unit.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.